DR. LIGENG TIAN B.M. NPI 1326379249

NPI Details

DR. Ligeng Tian, B.M. is a hematology and oncology internal medicine in Newport News, VA with 30 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Ligeng Tian, B.M. NPI is 1326379249. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

1051 LOFTIS BLVD
SUITE 100
NEWPORT NEWS, VA
ZIP 23606-069
Phone: (757) 873-9400
Fax: (757) 873-9420

The NPI 1326379249 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Blood test, clotting time (HCPCS:85610)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Protein measurement, serum (HCPCS:84165)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Unclassified drugs (HCPCS:J3490)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Vitamin d-3 level (HCPCS:82306)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Magnesium level (HCPCS:83735)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Urinalysis, manual test (HCPCS:81002)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Drawing of blood for a medical problem (HCPCS:99195)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)

The enumeration date for this NPI number is 1/15/2010 and was last updated on 3/12/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.